Nivolumab and Stereotactic Body Radiotherapy in Patients With Metastatic RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
Eur Urol 2021 Sep 30;[EPub Ahead of Print], C Masini, C Iotti, U De Giorgi, RS Bellia, S Buti, F Salaroli, I Zampiva, R Mazzarotto, C Mucciarini, MG Vitale, A Bruni, F Lohr, G Procopio, O Caffo, F Nole, F Morelli, S Baier, C Buttigliero, P Ciammella, G Timon, E Fantinel, G Carlinfante, A Berselli, C PintoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.